Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a
- PDF / 1,232,885 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 4 Downloads / 166 Views
ORIGINAL ARTICLE
Dipeptidyl peptidase‑4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population‑based cohort study Yi‑Chuan Chen1,3 · Tien‑Hsing Chen2,3 · Chi‑Chin Sun4,5 · Jau‑Yuan Chen1,3 · Shy‑Shin Chang6,7 · Ling Yeung3,4 · Yi‑Wen Tsai3,8,9 Received: 7 December 2019 / Accepted: 1 April 2020 © Springer-Verlag Italia S.r.l., part of Springer Nature 2020
Abstract Aims Dipeptidyl peptidase-4, a transmembrane glycoprotein expressed in various cell types, serves as a co-stimulator molecule to influence immune response. This study aimed to investigate associations between DPP-4 inhibitors and risk of autoimmune disorders in patients with type 2 diabetes mellitus in Taiwan. Methods This retrospective cohort study used the nationwide data from the diabetes subsection of Taiwan National Health Insurance Research Database between January 1, 2009, and December 31, 2013. Cox proportional hazards models were developed to compare the risk of autoimmune disorders and the subgroup analyses between the DPP-4i and DPP-4i-naïve groups. Results A total of 774,198 type 2 diabetic patients were identified. The adjusted HR of the incidence for composite autoimmune disorders in DPP-4i group was 0.56 (95% CI 0.53–0.60; P
Data Loading...
